Face-to-Face Service Enterprise Forum
On March 24th, a delegation led by Wang Linlin, Director of the Suzhou Inspection Branch of the Jiangsu Provincial Drug Administration and Director of the Suzhou Review and Verification Center, came to Taiwan to hold a “Face-to-Face” seminar for service enterprises, listen to their voices, respond to their demands, and help high-quality development of the biomedical industry. Zhang Jiufeng, Deputy Director of Suzhou Inspection Branch, Director of Suzhou Sub Center, and relevant department heads attended the event, accompanied by Zhang Zhan, vice mayor of Taicang Municipal People’s Government, and Wang Xiaohong, secretary of the Party Committee of Shaxi Town, Taicang City. Dr. Tammy Tan, CEO of HymonBio, was invited to participate.
At the symposium, Dr. Tan focused on the filing and approval of medical devices, classification and identification of special products, and inspection and testing of services encountered in the process of enterprise development. Relevant departments responded to the demands and coordinated to offer solutions.
Director Wang Linlin pointed out that since last year, the Suzhou Inspection Sub-Bureau and Suzhou Sub-center have actively served the biomedical industry to promote and empower it, and have done a lot of work in helping enterprises, facilitating services, regulatory innovation, business training, and policy publicity. Taicang is the first stop of this year’s “face-to-face” service, and it is hoped that with this as a starting point, the government, industrial parks and enterprises will form a joint force to improve the efficiency and implementation of policies, make practical results and achievements together, make a good start for the “face-to-face” service throughout the year, and jointly contribute wisdom and impetus to promoting Suzhou’s No. 1 industry to reach a new peak.
Photo: Director Wang Linlin
Vice Mayor Zhang Zhan emphasized the city has adhered to the biological medicine industry as a strategic emerging industry for key development, and has formed a pattern of “one park with two wings”. The influence of the “Taicang Pharmaceutical Valley” has continuously increased. The city will aim at first-class industrial bases at home and abroad, continue to sound the momentum of construction, accelerate the building of characteristic biomedical industry clusters in the Yangtze River Delta, strive to achieve a biomedical industry output value exceeding 50 billion yuan by 2025, and fully promote the rise and take-off of our biomedical industry innovation clusters.
Post time: Mar-28-2023